Daniel Shelly, Ph.D., Chief Business Development Officer

April 11 | 3:45pm | Salone dei Cavalieri, Section 2

Gdansk, Poland


PolTREG S.A. is a clinical-stage European biotechnology company developing T-regulatory cell (Tregs) therapies for autoimmune diseases including Type-1 Diabetes (T1D), Multiple Sclerosis (MS), and AMS. PolTREG has completed four clinical trials with more than 100 patients treated with Tregs. PTG-007 autologous treatment for early-onset T1D is ready for Phase 2/3 clinical trial, after a Phase 2 trial showed half of patients in clinical remission 24 months into the study. The company will launch a Phase 2 clinical trial for PTG-007 presymptomatic T1D in the second half of 2024. In MS, the company will launch Phase 2 trials for PTG-007 in the second half of 2024 for RRMS and PPMS. PolTREG is also developing engineered Tregs, including CAR-Tregs, antigen-specific Tregs and TCR-Tregs, all of which are in the preclinical stage. PolTREG has completed construction on one of the largest, state of the art, cGMP manufacturing facilities in Europe.


By using this website you agree to accept our Privacy Policy and Terms & Conditions